Small Molecule vs Psychedelic — Neurology Deal Terms Comparison
Market Analysis
In neurology, Small Molecule and Psychedelic represent two of the most actively transacted modalities. At Phase 2, Small Molecule deals carry a median total deal value of $3.0B with $343M upfront, compared to $3.3B total value and $378M upfront for Psychedelic. The valuation difference reflects distinct risk-reward profiles, manufacturing complexity, and competitive dynamics.
Milestone structures diverge between the two modalities. Small Molecule development milestones average $890M versus $978M for Psychedelic. Commercial milestones are $836M for Small Molecule and $919M for Psychedelic. Royalty rates range from 12.4%-19.8% for Small Molecule and 12.7%-20.3% for Psychedelic.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
How do Small Molecule and Psychedelic deal terms compare in neurology?
Which modality commands higher royalty rates: Small Molecule or Psychedelic?
How do milestone structures differ between Small Molecule and Psychedelic?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,400+ biopharma licensing deals.
Start CalculatingNeed a decision for one asset?
The Deal Intelligence Brief turns this landscape into a decision for one asset — a signed recommendation with ask, floor and walk-away, cited comparables, buyers ranked on evidence, and a 24-month catalyst calendar. Reviewed by the Managing Partner; delivered within 24 hours of the intake call.